The abstract is read at the publisher; the summary is JClub's.
Next-generation oncolytic virotherapy is positioned as an antigen-agnostic in situ cancer vaccination approach that can prime T cells against patient neoantigens without relying on pre-existing tumour-specific T cells.
- Why it matters: Immune checkpoint inhibitors and early oncolytic viruses are limited by dependence on pre-existing tumour-specific T cells, creating an immunological ceiling because they have limited ability to generate tumour-specific T cells de novo.
- What they did: The Perspective outlines four development pillars for next-generation OVs, including intratumoural vaccination that triggers immunogenic cell death and neoantigen-driven priming, plus optimized payloads and revised efficacy end points and correlates.
- The result: Clinical observations cited include T cell clonotype broadening, abscopal tumour regression, and survival benefit in ICI-refractory patients, supporting an OV-prime, ICI-amplify strategy and a systemic immune-reprogramming role delivered locally.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.